News blog

Updates from Europe PMC, a global database of life sciences literature

Europe PMC team

 | 2 April 2013


My reflections on the Access to Understanding competition

By Claire Sand,
Institute of Pharmaceutical Science, King’s College London

The Access to
Understanding competition had instant appeal for me because it seemed to
combine my two greatest interests – science and writing. I have always been
fascinated with the human body (particularly in disease), and am currently
working on my PhD in cardiovascular research, but having been an avid reader
all my life, I have an equally strong interest in language and semantics. I’ve
often thought of medical journalism as a potential future career option, but
never had the opportunity to test my skills and gain feedback from readers
outside of academic science. Placing in the top three has provided me with
validation that this is a viable path to take, and I feel encouraged and
inspired to pursue this type of writing further.

Coming from a
family of non-scientists I have always been keen to share exciting discoveries
(whether my own or others’) in terms that won’t be off-putting. In addition to
the personal satisfaction that can be gained from sparking scientific interest
in non-experts, I also believe that this type of public engagement is essential
on a number of other levels. I have often found non-scientists to be refractory
to hearing about research because they have preconceived notions that they
won’t understand, or that they are being patronised. Science as a profession
(and especially animal research) seems to be shrouded in mystery, and is
generally viewed at best with disinterest, and at worst with suspicion.

When people ask
me what I do for a living, my reply of “I work in medical science” is often met
with “Oh right” and a rapid change of subject – people don’t seem to have a
concept of what this job actually involves, and are usually not particularly
keen to find out, or don’t know what questions to ask. At first this reaction
surprised me: medical breakthroughs always elicit great public excitement (and
praise of doctors), but I am becoming increasingly aware of an information
‘black hole’ in medical progress; many people are entirely unaware of the years
of lab work that go into understanding a disease and developing new drugs to
target it. This is, more than anything, the result of poor communication by
scientists. In a time where money for research is more and more difficult to
come by, we as scientists should be trying to get people excited about our
research. Raising awareness of the origin of medicines, and engaging with both
the public and policy makers is the only way to ensure the future of scientific
funding. I am hopeful that down the line the efforts of public engagement
schemes like Access to Understanding will demystify the process of medical
research and will open more doors into the extraordinary and awe-inspiring
world of science.

Note: Claire was one of the winners (awarded
joint second place) of the 2013
Access to Understanding science-writing competition for
her entry ‘Blood vessels from skin: the new frontier in tissue engineering’,
which describes research published in the article ‘Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels‘.

Post a comment

I agree to the limited use of my personal data as described in the Europe PMC advanced user services privacy policy.

Creative Commons Licence
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Subscribe to the Europe PMC News blog to receive the latest updates

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Partnerships & funding

Europe PMC is a service of the Europe PMC Funders' Group, in partnership with EMBL’s European Bioinformatics Institute (EMBL-EBI); and in cooperation with the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NCBI/NLM) . It includes content provided to the PubMed Central (NLM/PMC) archive by participating publishers.